NRAS and cutaneous melanoma: The aim of the current study was to determine the BRAF and NRAS mutational status of nodal metastases in a large homogeneous group of cutaneous melanoma patients (BRAF inhibitor-naive patients with clinically detected regional nodal metastases), and to correlate those results with the clinical data and patient survival.